LifeMD climbs after offering Novo's Ozempic at $499 a month

LifeMD

30/09/2025 13:57

** Shares of telehealth firm LifeMD LFMD.O rise 2.5% to $6.60 premarket

** Company says it has partnered with Novo Nordisk NOVOb.CO to offer its diabetes drug Ozempic at $499 per month to eligible U.S. patients

** Through the partnership, eligible self-pay and uninsured patients, as well as insured patients whose plans do not cover GLP-1 therapies, will now have direct access to Ozempic

** Up to last close, shares up 30% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))